Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

actavis group ptc ehf. - indapamid (vandfri) - depottabletter - 1,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

les laboratoires servier - indapamid (vandfri) - depottabletter - 1,5 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

camurus ab - buprenorphin - opioid-relaterede lidelser - andre narkotika stoffer - behandling af opioidafhængighed inden for rammerne af en medicinsk, social og psykologisk behandling. behandlingen er beregnet til brug hos voksne og unge i alderen 16 år eller over.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

vitabalans oy - melatonin - tabletter - 3 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - ef-erhvervede infektioner - antibakterielle midler til systemisk brug, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 og 5. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..

Den Europæiske Union - dansk - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfom, mantelcelle - antineoplastiske midler - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft afvisning - immunosuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

n.v. organon - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminer til systemisk brug, - aerius er indiceret til lindring af symptomer forbundet med allergisk rhinitis;urticaria.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - brinzolamid, timolol maleate - glaucoma, open-angle; ocular hypertension - oftalmologiske - reduktion af intraokulært tryk (iop) hos voksne patienter med åbenvinklet glaukom eller okulær hypertension, for hvem monoterapi giver utilstrækkelig iop reduktion.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

n.v. organon - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminer til systemisk brug, - azomyr is indicated for the relief of symptoms associated with:allergic rhinitis (see section 5. 1)urticaria (see section 5.